QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=FE390919606FA9CDF00B0C61A4202833;jsessionid=3F5DFB266FBDD5A19ACBEA654DC8EC54;jsessionid=CF323899DE1C3F386C07DC837372A6D7;jsessionid=EF7AFDC64315D899F8C1AE12B77308BF;jsessionid=7483229CB7C607085EC2844DC3B948D3;jsessionid=82D6D271DA790044292737271EEAE8A1;jsessionid=3B03565216A86EA33E06D85028EF3EA7;jsessionid=854EAB95EB9D494F622EA3FD894C55D3 (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=FE390919606FA9CDF00B0C61A4202833;jsessionid=3F5DFB266FBDD5A19ACBEA654DC8EC54;jsessionid=CF323899DE1C3F386C07DC837372A6D7;jsessionid=EF7AFDC64315D899F8C1AE12B77308BF;jsessionid=7483229CB7C607085EC2844DC3B948D3;jsessionid=82D6D271DA790044292737271EEAE8A1;jsessionid=3B03565216A86EA33E06D85028EF3EA7;jsessionid=854EAB95EB9D494F622EA3FD894C55D3